Rare Vascular Diseases: Scoping Review with ☸️SAIMSARA
SAIMSARA Journal · 11.04.2026 · 1 (1)
DOI: 10.62487/saimsaraac7391aa ↗Kurz gefasst
Scoping Review in der Zeitschrift SAIMSARA Journal, online erschienen am 11.04.2026. Die Arbeit nennt 75 Literaturangaben.
Abstract (Originalsprache)
The aim of this paper is to synthesize current evidence regarding the pathophysiology, diagnostic advancements, and therapeutic strategies for rare vascular diseases, utilizing a diverse range of clinical and experimental studies to identify common themes in vascular dysfunction and management. The review utilises 66 original studies with 6238 total participants (topic deduplicated ΣN). This evidence map suggests that rare vascular disease is unified less by a single phenotype than by recurrent disruptions in vascular signaling, extracellular matrix integrity, endothelial behavior, and vascular smooth muscle cell homeostasis, with notable quantitative signals including a roughly 30% contribution of chromatin modifier and EPHB4 variants in vein of Galen malformations, a 25.7-year mean diagnostic delay in hereditary haemorrhagic telangiectasia, a 4.7% annual major vascular event risk in celiprolol-treated vascular Ehlers-Danlos syndrome, and partial response or stabilization in most reported kaposiform lymphangiomatosis cases treated with sirolimus. Across the major topics, the strongest recurring pattern is that molecularly defined subgroups—such as COL5A1-, DIAPH1-, VEGFC-, and NOTCH-related vasculopathies—help explain why these disorders present with widely different manifestations yet may still converge on shared pathways of remodeling, fragility, fibrosis, and hemorrhage. The review also highlights a practical clinical message: earlier recognition supported by targeted imaging and genetic evaluation may reduce misdiagnosis and enable more tailored surveillance or therapy in conditions that are otherwise discovered only after major complications. At the same time, the mapped evidence remains dominated by rare-disease observational and case-based literature, so therapeutic signals should be interpreted as promising rather than definitive. Future research should prioritize multicenter longitudinal cohorts and mechanism-linked interventional studies that connect genotype, vascular phenotype, and treatment response across these heterogeneous but biologically informative disorders.
Zitieren
APA
(2026). Rare Vascular Diseases: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal, 1(1). https://doi.org/10.62487/saimsaraac7391aa
Vancouver
Rare Vascular Diseases: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal. 2026;1(1). doi:10.62487/saimsaraac7391aa
BibTeX
@article{euvimed2026,
title = {Rare Vascular Diseases: Scoping Review with ☸️SAIMSARA},
journal = {SAIMSARA Journal},
year = {2026},
volume = {1},
number = {1},
doi = {10.62487/saimsaraac7391aa}
}
EUVIMED